Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

th pegylated interferon and ribavirin. The actual timing for the initiation of Phase II studies may depend on a number of factors, including FDA review timelines, the timing of any potential transaction around ANA598 or ANA773, available cash resources and funding activities, and the engagement of clinical sites.

14 Day Healthy Volunteer Study

Anadys recently completed dosing healthy volunteers in a 14-day study conducted to extend the safety and pharmacokinetic profile of ANA598. Thirty subjects participated in the study, with eight subjects receiving ANA598 and two subjects receiving placebo at each dose level (400 mg once-daily, 800 mg once-daily and 600 mg bid). Subjects received ANA598 or placebo on day one followed by pharmacokinetic assessment over days two and three and received subsequent doses consecutively on days four through fourteen. Preliminary results from the study indicate that ANA598 was generally well-tolerated in all cohorts with no serious adverse events, although three subjects receiving ANA598 (two in the 800 mg once-daily cohort and one in the 600 mg bid cohort) developed grade 2 rash and discontinued treatment after either six or seven days of consecutive dosing. There were no other instances of rash in this or any other study of ANA598. Data receipt and analysis from this study is continuing, and the Company expects to present the results at a clinical conference later this year. The Company believes the results of this study, combined with the results of the Phase Ib study in HCV patients, contribute to the attractive profile of ANA598 as an antiviral likely to be active in long-term studies in combination with pegylated interferon and ribavirin, and help position the program to be ready for Phase II in mid-2009.

Long-term Toxicology Studies

In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598, of 26 weeks duration in rats a
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Pharmaceuticals, Inc. (Nasdaq: CADX ) today announced that ... of its common stock at a price to the public ... of the shares, after deducting the underwriting discounts and commissions ... million.  Cadence has granted the underwriters for the offering a ...
... NEW YORK, Nov. 15, 2011 Reportlinker.com ... is available in its catalogue: ... East Asia ... analysis of four pharmaceutical markets that present ...
Cached Medicine Technology:Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3The Outlook for Pharmaceuticals in North East Asia 2The Outlook for Pharmaceuticals in North East Asia 3The Outlook for Pharmaceuticals in North East Asia 4
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... . A ... A team led by Ludwik Leibler from the Laboratoire ... Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits Paris ... principle of adhesion by aqueous solutions of nanoparticles can ... tissues. This easy-to-use gluing method has been tested on ...
(Date:4/17/2014)... in benign prostate tissue was associated with high-grade, ... found even in those with low prostate-specific antigen ... Cancer Epidemiology, Biomarkers & Prevention , a ... , An analysis of prostate tissue biopsies collected ... the Prostate Cancer Prevention Trial (PCPT) found that ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
... Nov. 26 David B. Snow,chairman & chief executive ... to address the Merrill Lynch & Co., Inc. 2007 ... presentation at Merrill Lynch headquarters, New York, will begin ... and Richard J.,Rubino, CPA, Medco,s controller and chief accounting ...
... CHICAGO, Nov. 26 All-terrain vehicles (ATVs) pose a,serious ... largest study ever,conducted of ATV injuries in children. The ... Radiological Society of North America (RSNA)., "Our experience ... be restricted," said Chetan C. Shah, M.D., radiology fellow ...
... women have a different understanding of screening mammography ... the findings of a Boston University Medical Center ... the Radiological Society of North America (RSNA). , ... ethnic and socioeconomic groups, said Nazia F. Jafri, ...
... PHILADELPHIA Researchers at the University of Pennsylvania School ... transcranial magnetic stimulation (TMS) a non-invasive technique that ... through the scalp is a safe and effective, ... major depression who have tried other treatment options without ...
... and its there in bright medical images: evidence of ... secondhand cigarette smoke. For the first time, researchers have ... but not previously detectable with medical imaging tools. ... public health efforts to restrict secondhand smoke. , ...
... FAAN, FAHA, a clinical professor of neurology at Boston ... the Framingham Heart Study, was recently awarded the Stroke ... award was presented at the AHAs recent Scientific Sessions ... Award recognizes and encourages those who actively work to ...
Cached Medicine News:Health News:Medco CEO to Present at the Merrill Lynch & Co., Inc. 2007 Health Services Investor Conference 2Health News:Injury Report Shows All-Terrain Vehicles Not Child's Play 2Health News:Injury Report Shows All-Terrain Vehicles Not Child's Play 3Health News:Attitudes toward mammography differ across ethnicities, cultures, backgrounds 2Health News:Penn research shows transcranial magnetic stimulation effective in treating major depression 2Health News:Secondhand smoke damages lungs, MRIs show 2
... and removal in the urinary tract. The nitinol ... shape following extreme torsion. The unique tipless design ... basket to open at the base of the ... reduces the likelihood of mucosal damage and perforation. ...
... Filiform Spiral Tip 12 Inch , 20 ... female thread. Available in 3,4,5 6Fr. These ... strong but flexible polymer material and have ... other brands. They are manufactured to the ...
... for stone manipulation and removal in the urinary ... Delta Wire. The revolutionary triangular shape of Delta ... largest possible wire mass. The superior mass of ... qualities of nitinol alloy, creates a basket with ...
... SILASTIC Brand Latex Foley Catheter, Smooth, ... build-up, Firm, but flexible, latex-based construction ... length - round tip with two ... (336xx) or two staggered eyes and ...
Medicine Products: